Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy

Neoplasia

Volumn 7, Issue 11, 2005, Pages 1020-1029

  Bilsland, Alan E ^a   Fletcher Monaghan, Aileen ^a   Keith, W Nicol ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cre recombinase; Gene therapy; hTERT; hTR; Telomerase

Indexed keywords

CRE RECOMBINASE; LUCIFERASE; OXIDIZED LOW DENSITY LIPOPROTEIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; DNA BINDING PROTEIN; RECOMBINANT PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOMEGALOVIRUS; GENE SWITCHING; GENE THERAPY; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; POLYADENYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; SIMIAN VIRUS 40; ADENOCARCINOMA; BLADDER TUMOR; CARCINOMA; FEMALE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; METABOLISM; METHODOLOGY; NEOPLASM; TUMOR CELL LINE;

ADENOCARCINOMA; CARCINOMA; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; GENE THERAPY; HUMANS; NEOPLASMS; PROMOTER REGIONS (GENETICS); RECOMBINANT PROTEINS; TELOMERASE; TRANSCRIPTION, GENETIC; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 33644825566     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05385     Document Type: Article

References (39)

1. Kim MM, Rivera MA, Botchkina IL, Shalaby R, Thor AD, and Blackburn EH (2001). A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation. Proc Natl Acad Sci USA 98, 7982-7987.
2. Autexier C, Pruzan R, Funk WD, and Greider CW (1996). Reconstitution of human telomerase activity and identification of a minimal functional region of the human telomerase RNA. EMBO J 15, 5928-5935.
3. Bachand F and Autexier C (2001). Functional regions of human telomerase reverse transcriptase and human telomerase RNA required for telomerase activity and RNA-protein interactions. Mol Cell Biol 21, 1888-1897.
4. Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, Kauffmann I, Garin-Chesa P, Rettig WJ, Damm K, and Schnapp A (2002). Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 277, 15566-15572.
5. El-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, and Martens UM (2005). Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 105, 1742-1749.
6. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JH, Meyerson M, and Weinberg RA (1999). Inhibition of telomerase limits the growth of human cancer cells. Nat Med 5, 1164-1170.
7. Naasani I, Seimiya H, Yamori T, and Tsuruo T (1999). FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res 59, 4004-4011.
8. Zhang X, Mar V, Zhou W, Harrington L, and Robinson MO (1999). Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 13, 2388-2399.
9. Keith WN, Bilsland A, Hardie M, and Evans TRJ (2004). Cancer cell immortality-telomerase as a target for novel cancer gene therapies. Nat Clin Pract Oncol 1, 88-96.
10. Keith WN, Bilsland A, Evans TR, and Glasspool RM (2002). Telomerase-directed molecular therapeutics. Expert Rev Mol Med 2002, 1-25.
11. Lavelle F, Riou JF, Laoui A, and Mailliet P (2000). Telomerase: a therapeutic target for the third millennium? Crit Rev Oncol Hematol 34, 111-126.
12. White LK, Wright WE, and Shay JW (2001). Telomerase inhibitors. Trends Biotechnol 19, 114-120.
13. Majumdar AS, Hughes DE, Lichtsteiner SP, Wang Z, Lebkowski JS, and Vasserot AP (2001). The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther 8, 568-578.
14. Takeda T, Inaba H, Yamazaki M, Kyo S, Miyamoto T, Suzuki S, Ehara T, Kakizawa T, Hara M, DeGroot LJ, et al. (2003). Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter. J Clin Endocrinol Metab 88, 3531-3538.
15. Plumb JA, Bilsland A, Kakani R, Zhao J, Glasspool RM, Knox RJ, Evans TR, and Keith WN (2001). Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 20, 7797-7803.
16. Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, McGregor F, Jeffry Evans TR, Ganly I, Knox RJ, Plumb JA, and Nicol Keith W (2003). Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 22, 370-380.
17. Liu J, Zou WG, Lang MF, Luo J, Sun LY, Wang XN, Qian QJ, and Liu XY (2002). Cancer-specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter. Int J Oncol 21, 661-666.
18. Komata T, Koga S, Hirohata S, Takakura M, Germano IM, Inoue M, Kyo S, Kondo S, and Kondo Y (2001). A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter. Int J Oncol 19, 1015-1020.
19. Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H, Srinivasula SM, Barna BP, Germano IM, Takakura M, et al. (2001). Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 61, 5796-5802.
20. Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S, and Kondo S (2000). A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 11, 1397-1406.
21. Gu J, Zhang L, Huang X, Lin T, Yin M, Xu K, Ji L, Roth JA, and Fang B (2002). A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. Oncogene 21, 4757-4764.
22. Groot-Wassink T, Aboagye EO, Glaser M, Lemoine NR, and Vassaux G (2002). Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther 13, 1723-1735.
23. Lin T, Huang X, Gu J, Zhang L, Roth JA, Xiong M, Curley SA, Yu Y, Hunt KK, and Fang B (2002). Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 21, 8020-8028.
24. Kim E, Kim JH, Shin HY, Lee H, Yang JM, Kim J, Sohn JH, Kim H, and Yun CO (2003). Ad-mTERT-Delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 14, 1415-1428.
25. Boyd M, Mairs RJ, Keith WN, Ross SC, Welsh P, Akabani G, Owens J, Vaidyanathan G, Carruthers R, Dorrens J, et al. (2004). An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated by stander effects. J Gene Med 6, 937-947.
26. Fullerton NE, Boyd M, Mairs RJ, Keith WN, Alderwish O, Brown MM, Livingstone A, and Kirk D (2004). Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate. Prostate Cancer Prostatic Dis 7, 355-363.
27. Fullerton NE, Mairs RJ, Kirk D, Keith WN, Carruthers R, McCluskey AG, Brown M, Wilson L, and Boyd M (2005). Application of targeted radiotherapy/gene therapy to bladder cancer cell lines. Eur Urol 47, 250-256.
28. Wang J, Yao M, Zhang Z, Gu J, Zhang Y, Li B, Sun L, and Liu X (2003). Enhanced suicide gene therapy by chimeric tumor-specific promoter based on HSF1 transcriptional regulation. FEBS Lett 546, 315-320.
29. Cui W, Gusterson B, and Clark AJ (1999). Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway. Gene Ther 6, 764-770.
30. Anlezark GM, Melton RG, Sherwood RF, Coles B, Friedlos F, and Knox RJ (1992). The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954): I. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 44, 2289-2295.
31. Sauer B (1998). Inducible gene targeting in mice using the Cre/lox system. Methods 14, 381-392.
32. Ghosh K and Van Duyne GD (2002). Cre-loxP biochemistry. Methods 28, 374-383.
33. Lin X, Fischer AH, Ryu KY, Cho JY, Sferra TJ, Kloos RT, Mazzaferri EL, and Jhiang SM (2004). Application of the Cre/loxP system to enhance thyroid-targeted expression of sodium/iodide symporter. J Clin Endocrinol Metab 89, 2344-2350.
34. Nagayama Y, Nishihara E, Iitaka M, Namba H, Yamashita S, and Niwa M (1999). Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system. Cancer Res 59, 3049-3052.
35. Yoshimura I, Ikegami S, Suzuki S, Tadakuma T, and Hayakawa M (2002). Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system. J Urol 168, 2659-2664.
36. Ueda K, Iwahashi M, Nakamori M, Nakamura M, Matsuura I, Yamaue H, and Tanimura H (2001). Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res 61, 6158-6162.
37. Takikawa H, Mafune K, Hamada H, Nettelbeck DM, Muller R, Makuuchi M, and Kaminishi M (2003). An advanced strategy of enhanced specific gene expression for hepatocellular carcinoma. Int J Oncol 22, 1051-1056.
38. Ringrose L, Lounnas V, Ehrlich L, Buchholz F, Wade R, and Stewart AF (1998). Comparative kinetic analysis of FLP and cre recombinases: mathematical models for DNA binding and recombination. J Mol Biol 284, 363-384.
39. Martin SS, Chu VC, and Baldwin E (2003). Modulation of the active complex assembly and turnover rate by protein-DNA interactions in Cre-LoxP recombination. Biochemistry 42, 6814-6826.